Companies / PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc.

Nasdaq: PMCBCIK 1157075LAS VEGAS, NV

Financials · FY2026

Revenue$0
Net income$-19.42M
Total debt$2.46M
Cash$18.60M
Diluted EPS$-2.77
Shares outstanding10.7M

Ownership

10.7M shares outstanding · as of Jul 24, 2026
5.7%Insiders
Ownership
Insiders5.67%608,750
Institutions9.49%1,018,405
Public float84.84%9,108,494

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 5

View all →
Insider% of sharesShares
Silverman JoshuaCEOCEO and President · Director
3.88%416,250
Schechter JonathanDirector
1.79%192,500
Abecassis Michael MDirector
——
Walker Wayne RemellDirector
——
Weinstein RobertDirector
——

Institutional holders 28

View all →
HolderValue% of shares
Citadel Advisors LLC$166.3K2.14%
Geode Capital Management, LLC$130.2K1.82%
Sabby Management, LLC$72.4K0.93%
Vanguard Group Inc$54.2K0.70%
Renaissance Technologies LLC$37.6K0.53%
Northern Trust Corp$25.8K0.33%
Schonfeld Strategic Advisors LLC$19.0K0.24%
Simplex Trading, LLC$18.7K0.24%
Two Sigma Securities, LLC$17.8K0.23%
XTX Topco Ltd$17.7K0.23%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jan 7, 2026Silverman Joshua
CEO
BuyCommon Stock$33.3K+40K
+10.63%
416,250
3.88% of shares
low
Jan 6, 2026Silverman Joshua
CEO
BuyCommon Stock$23.7K+30K
+8.66%
376,250
3.50% of shares
low
Jan 5, 2026Silverman Joshua
CEO
BuyCommon Stock$23.5K+30K
+9.49%
346,250
3.23% of shares
low
Jan 7, 2026Schechter Jonathan
Director
BuyCommon Stock$16.9K+20K
+11.59%
192,500
1.79% of shares
low
Jan 6, 2026Schechter Jonathan
Director
BuyCommon Stock$15.8K+20K
+13.11%
172,500
1.61% of shares
low
Jan 5, 2026Schechter Jonathan
Director
BuyCommon Stock$15.6K+20K
+15.09%
152,500
1.42% of shares
low
Mar 31, 2026Weinstein Robert
Director
GrantStock Option (Right to Buy)—+119K
119,170
1.11% of shares
low
Mar 31, 2026Walker Wayne Remell
Director
GrantStock Option (Right to Buy)—+119K
119,170
1.11% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Mitchell P. KopinPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
PMCBCommon StockEquity71715X203BBG000BBVY94